Morgan Stanley
JANX icon

Morgan Stanley’s Janux Therapeutics JANX Stock Holding History

Morgan Stanley’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Buy
836,966
+133,026
+19% +$1.93M ﹤0.01% 3497
2026
Q1 		$9.78M Buy
703,940
+85,555
+14% +$1.17M ﹤0.01% 3583
2025
Q4 		$8.53M Buy
618,385
+122,750
+25% +$2.89M ﹤0.01% 3741
2025
Q3 		$12.1M Buy
495,635
+179,904
+57% +$4.38M ﹤0.01% 3373
2025
Q2 		$7.29M Buy
315,731
+33,304
+12% +$878K ﹤0.01% 3740
2025
Q1 		$7.63M Buy
282,427
+64,596
+30% +$2.43M ﹤0.01% 3572
2024
Q4 		$11.7M Buy
217,831
+77,367
+55% +$4.09M ﹤0.01% 3282
2024
Q3 		$6.38M Buy
140,464
+58,666
+72% +$2.55M ﹤0.01% 3778
2024
Q2 		$3.43M Sell
81,798
-39,433
-33% -$1.85M ﹤0.01% 4187
2024
Q1 		$4.56M Buy
121,231
+53,783
+80% +$1.17M ﹤0.01% 3980
2023
Q4 		$724K Buy
67,448
+46,992
+230% +$406K ﹤0.01% 5122
2023
Q3 		$206K Buy
20,456
+1,975
+11% +$22.8K ﹤0.01% 5563
2023
Q2 		$219K Sell
18,481
-15,023
-45% -$201K ﹤0.01% 5612
2023
Q1 		$405K Buy
33,504
+16,020
+92% +$267K ﹤0.01% 5371
2022
Q4 		$230K Sell
17,484
-123,996
-88% -$1.81M ﹤0.01% 5607
2022
Q3 		$1.92M Buy
141,480
+113,747
+410% +$1.52M ﹤0.01% 4461
2022
Q2 		$337K Sell
27,733
-10
-0% -$118 ﹤0.01% 5621
2022
Q1 		$398K Buy
27,743
+13,264
+92% +$217K ﹤0.01% 5534
2021
Q4 		$285K Buy
14,479
+7,777
+116% +$163K ﹤0.01% 5874
2021
Q3 		$145K Buy
6,702
+6,602
+6,602% +$190K ﹤0.01% 6170
2021
Q2 		$2K Buy
+100
New +$2.23K ﹤0.01% 7526

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Morgan Stanley's JANX Position: Q2 2026 in Review

Morgan Stanley increased its Janux Therapeutics (JANX) stake by 19% in Q2 2026, buying an estimated $1.93M and bringing the position to 836,966 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3497.

Morgan Stanley first reported a position in JANX in Q2 2021 and has held it in 21 quarters since. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Morgan Stanley held 836,966 shares of Janux Therapeutics worth $12.9M as of Q2 2026.
  • Morgan Stanley bought 133,026 Janux Therapeutics shares in Q2 2026, an estimated $1.93M.
  • Janux Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3497 holding.
  • Morgan Stanley first reported a position in Janux Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.